MASHINIi

Taysha Gene Therapies, Inc..

TSHA.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

Taysha Gene Therapies, Inc. is a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). The company's pipeline includes several gene therapy programs targeting rare genetic d...Show More

Ethical Profile

Mixed.

Taysha Gene Therapies (TSHA.US) shows a strong commitment to addressing rare CNS diseases. In the REVEAL Phase 1/2 trial for TSHA-102 (Rett syndrome), 100% of 10 patients reportedly gained or regained at least one developmental milestone, leading to FDA support for a pivotal trial. Astellas' $50 million investment and a $200 million public offering further support their gene therapy development. However, as a clinical-stage biotech, the company's preclinical research fundamentally relies on animal testing, including studies in mice, which critics point to as conflicting with "Kind to Animals" values. Information on fair pay, ethical sourcing, and environmental impact is currently limited.

Value Scores

Better Health for All30
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect20
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals-40
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

30

Taysha Gene Therapies develops AAV-based gene therapies for rare monogenic CNS diseases.

1
In the REVEAL Phase 1/2 clinical trial for TSHA-102, 100% of 10 patients (ages 6-21) gained or regained at least one developmental milestone.
2
No treatment-related serious adverse events or dose-limiting toxicities were reported in this trial.
3
The company's products are investigational gene therapies, not revenue-generating activities with negative health outcomes.
4
The trial design for TSHA-102 is informed by longitudinal data from the Rett Syndrome Natural History Study, which has collected data from over 1,000 participants over 15 years, and the IRSF Rett Syndrome Registry.
5

Fair Money & Economic Opportunity

0

Taysha Gene Therapies, Inc. is a gene therapy company focused on developing treatments for monogenic diseases, not a financial institution.

1
The provided articles contain no specific, concrete data points related to lending, insurance, or other financial services offered to consumers.
2
Therefore, all KPIs under the 'Fair Money & Economic Opportunity' value, which are designed to assess financial institutions, are not applicable and cannot be scored based on the available evidence.

Fair Pay & Worker Respect

20

The company's worker engagement score is 4.2 out of 5, which translates to 84%.

1
This places it in the 80-tier. Additionally, there are zero regulatory actions listed in one article
2
and no information on violations, fines, or compliance issues in another,
3
indicating zero fines or violations.

Fair Trade & Ethical Sourcing

0

No evidence available to assess Taysha Gene Therapies, Inc. on Fair Trade & Ethical Sourcing.

Honest & Fair Business

0

No evidence available to assess Taysha Gene Therapies, Inc. on Honest & Fair Business.

Kind to Animals

-40

Taysha Gene Therapies conducts preclinical animal testing, as evidenced by its use of mice in a study for TSHA-102 gene therapy, where 15,000-25,000 animals are used per year.

1
The provided articles do not contain specific quantitative data or policy details required to assess the company against other 'Kind to Animals' KPIs, such as the extent of alternative testing methods employed or the company's animal testing policy.

No War, No Weapons

0

No evidence available to assess Taysha Gene Therapies, Inc. on No War, No Weapons.

Planet-Friendly Business

0

No evidence available to assess Taysha Gene Therapies, Inc. on Planet-Friendly Business.

Respect for Cultures & Communities

0

No information regarding Taysha Gene Therapies, Inc. (TSHA.US) or its performance related to Respect for Cultures & Communities was found in the provided articles. The articles primarily discuss the financial results of Velan Inc.

1
and general information about clinical trials,
2
neither of which is relevant to TSHA.US or the specified ethical value.

Safe & Smart Tech

0

No evidence available to assess Taysha Gene Therapies, Inc. on Safe & Smart Tech.

Zero Waste & Sustainable Products

0

No specific, measurable evidence was found in the provided articles for any of the Key Performance Indicators related to Zero Waste & Sustainable Products. The articles contained only high-level commitments regarding waste reduction and responsible disposal, which do not constitute concrete actions, outcomes, or quantitative data required for scoring against the rubric.

1

Own Taysha Gene Therapies, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.